Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, Bataillon G, Ouine B, Dahmani A, Montaudon E, Painsec P, Chateau-Joubert S, Laetitia F, Larcher T, Vacher S, Chemlali W, Briaux A, Melaabi S, Salomon AV, Guinebretiere JM, Bieche I, Marangoni E.
Coussy F, et al. Among authors: bataillon g.
Theranostics. 2020 Jan 1;10(4):1531-1543. doi: 10.7150/thno.36182. eCollection 2020.
Theranostics. 2020.
PMID: 32042320
Free PMC article.